Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Karen Knudsen

Tracked across 2 events · 133 articles · First seen Apr 17, 2026 · Last active Aug 26, 2026

Sentiment
50
Attention
7
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
7 60
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: As CEO of Parker Institute for Cancer Immunotherapy, Knudsen said the results could signal a new era for treating solid-tumor cancers, highlighting the broader implications for the field.
Aug 19, 2026 · 126 articles
2 40
Business
Impact: Karen Knudsen is the CEO of SAGT, expressing commitment to sustainable growth and operational excellence.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Karen Knudsen live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.